LEADER 03465nam  2200577Ia 450 
001 9910437605403321
005 20200520144314.0
010   $a1-4614-5380-1
024 7 $a10.1007/978-1-4614-5380-2
035   $a(CKB)2670000000530233
035   $a(EBL)1205300
035   $a(OCoLC)851971801
035   $a(SSID)ssj0000880114
035   $a(PQKBManifestationID)11454285
035   $a(PQKBTitleCode)TC0000880114
035   $a(PQKBWorkID)10873215
035   $a(PQKB)11503827
035   $a(DE-He213)978-1-4614-5380-2
035   $a(MiAaPQ)EBC1205300
035   $a(PPN)169135756
035   $a(EXLCZ)992670000000530233
100   $a20130425d2013      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aNovel immune potentiators and delivery technologies for next generation vaccines /$fManmohan Singh, editor
205   $a1st ed. 2013.
210   $aNew York $cSpringer$dc2013
215   $a1 online resource (367 p.)
300   $aIncludes index.
311   $a1-4614-5379-8 
311   $a1-4899-9228-6 
327   $aCritical parameters that govern the optimization of vaccine formulations -- Development of Biophysical assays to better understand vaccine formulation stability -- Rational design of vaccine formulations -- Monitoring stability and efficacy of multi-valent vaccine formulations.-  Overcoming challenges of multi component alum formulations.-  Delivery of various TLR adjuvants using alum platform -- History of use of emulsions for vaccine delivery -- MF59 o/w emulsion : History and safety over the last 2 decades -- Optimizing novel nanoemulsions for delivery of next generation antigens and adjuvants -- Modulating vaccine responses with innate immunity : Use of PLGA nanoparticles for delivering multiple TLR agonists -- Shape matters : Role of nanoparticle shape in induction of immune responses to a vaccine.        .
330   $aDevelopment of new-generation vaccines is now more challenging than ever, as identifying, purifying and evaluating vaccine antigens is a complex undertaking. Most importantly, once the relevant antigens have been identified, key focus then shifts to the development of suitable delivery systems and formulations to achieve maximum in vivo potency with minimum potential side effects. These novel formulations?many of which will be nanoparticulates?can deliver the antigens to the desired site, to the relevant antigen presenting cells, and prevent systemic exposure of the immune potentiators. The proposed book will outline all the critical steps that need to be considered for successful development of various types of nanoparticulate delivery systems for vaccine antigens. These contributions from leading experts in the area of vaccine formulation and delivery systems will tie in what is the most current status, including clinical evaluations with these novel vaccine technologies.
606   $aImmunology
606   $aVaccines$xBiotechnology
606   $aVaccines
615  0$aImmunology.
615  0$aVaccines$xBiotechnology.
615  0$aVaccines.
676   $a615.6
701   $aManmohan Singh$f1964 November 8-$01646559
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910437605403321
996   $aNovel immune potentiators and delivery technologies for next generation vaccines$94194156
997   $aUNINA